Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2020-04-09 AGM Information
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
Pharmanutra S.p.A. : pubblicato avviso convocazione Assemblea Ordinaria
AGM Information Classification · 1% confidence The document is an official regulatory announcement (Informazione Regolamentata) from Pharmanutra S.p.A. The subject line explicitly states: 'Pharmanutra S.p.A. : pubblicato avviso convocazione Assemblea Ordinaria' (Pharmanutra S.p.A.: published notice of call for Ordinary Shareholders' Meeting). The text details the date, time, location, and the agenda items for the upcoming Ordinary Shareholders' Meeting (Assemblea Ordinaria). Key agenda items include the approval of the 2019 Financial Statements and the appointment of the Board of Directors. This content directly relates to the formal notice and materials required for an Annual General Meeting (AGM). Since the document is the *notice* of the meeting and its agenda, it falls under the category for AGM-related materials, which is AGM-R (AGM Information). It is not the minutes (AGM-R is for presentations/materials), nor is it the proxy solicitation material (PSI), but the formal notice of the meeting itself.
2020-04-09 Italian
PHN- Operazione di Buy Back
Transaction in Own Shares Classification · 1% confidence The document is an official regulatory announcement (Informazione Regolamentata) from Pharmanutra S.p.A. dated April 6, 2020. The subject ('Oggetto') is 'PHN- Operazione di Buy Back' (Buy Back Operation). The text explicitly states that the Board of Directors ('CDA') resolved to submit a proposal to the upcoming Shareholders' Meeting ('Assemblea Ordinaria degli azionisti') authorizing the purchase and disposal of own shares ('autorizzazione all'acquisto e alla disposizione di azioni proprie'). This action—proposing a share repurchase program to shareholders—directly relates to changes in the company's capital structure or treasury stock management. This aligns best with the 'Share Issue/Capital Change' (SHA) or 'Transaction in Own Shares' (POS) categories. Since the core action is the *proposal* for a buyback program, which is a form of transaction in own shares, POS is the most specific fit. It is not a general financing update (CAP) but a specific treasury stock action. It is also not a mere announcement of a report (RPA) as it contains substantive corporate decision details.
2020-04-06 Italian
CS - PHN dati delle vendite del primo trimestre 2020
Earnings Release Classification · 1% confidence The document is an official communication (Informazione Regolamentata) from Pharmanutra S.p.A. dated April 3, 2020. The subject line ('Oggetto') explicitly states 'CS - PHN dati delle vendite del primo trimestre 2020' (Sales data for the first quarter 2020). The content details sales figures, growth percentages (+15% in Italy), and performance highlights for the first quarter of 2020, comparing them to the previous year. This is a preliminary announcement of periodic financial results, focusing on key highlights rather than a comprehensive report (like a 10-K or IR). Therefore, it fits the definition of an Earnings Release (ER). The document is short and contains an instruction 'Vedi allegato' (See attachment), but the core content *is* the earnings summary, making ER more appropriate than RPA, as it is the release itself, not just an announcement of a separate, attached report. Q1 2020
2020-04-03 Italian
CS - concessione brevetti India e USA 25_03_2020
Regulatory Filings Classification · 1% confidence The document is an official communication titled 'Informazione Regolamentata' (Regulated Information) from Pharmanutra S.p.A., dated March 25, 2020. The subject ('Oggetto') is 'CS - concessione brevetti India e USA' (CS - patent grants India and USA). The content details the granting of two new patents (one for SiderAL® in India and one for Cetilar® in the USA) and a new distribution agreement in Bulgaria. This type of announcement, which communicates specific, material, non-financial corporate events (like patent grants or new agreements) to the market, fits best under the general category of regulatory announcements or specific news releases. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a proxy statement (DEF 14A), and it is a specific piece of news, it is classified as a general Regulatory Filing (RNS), which serves as the catch-all for significant, non-standard announcements not covered by other specific codes. The document length (6602 chars) is substantial enough to be the primary communication, not just a notice of publication (RPA).
2020-03-25 Italian
PR PHN Financial Statements 31 12 2019
Earnings Release Classification · 1% confidence The document is an initial announcement of financial results for the fiscal year ending December 31, 2019. It contains key financial highlights (Revenue, EBITDA, Net Income, Net Financial Position), management commentary, and a summary of business performance. While it mentions the approval of the draft financial statements, it functions as the primary press release announcing these results to the market, which fits the definition of an Earnings Release (ER). FY 2019
2020-03-23 English
CS - PHARMANUTRA approvazione CDA Bilancio 31 12 2019
Earnings Release Classification · 1% confidence The document is a press release from PharmaNutra S.p.A. announcing the approval of its 2019 draft financial statements and consolidated financial statements by the Board of Directors. It includes key financial highlights (revenue, EBITDA, net income, dividend proposal) and management commentary. While it contains substantive financial data, it is structured as an initial announcement of results (Earnings Release) rather than the full, audited Annual Report document itself. Therefore, it is classified as an Earnings Release. FY 2019
2020-03-23 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.